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Endocannabinoids and striatal function: implications for
addiction-related behaviours
Fabricio A. Moreiraa,b, Bianca Juppb, David Belinc and Jeffrey W. Dalleyb,d
Since the identification and cloning of the major
cannabinoid receptor expressed in the brain almost
25 years ago research has highlighted the potential of drugs
that target the endocannabinoid system for treating
addiction. The endocannabinoids, anandamide and
2-arachidonoyl glycerol, are lipid-derived metabolites found
in abundance in the basal ganglia and other brain areas
innervated by the mesocorticolimbic dopamine systems.
Cannabinoid CB1 receptor antagonists/inverse agonists
reduce reinstatement of responding for cocaine, alcohol and
opiates in rodents. However, compounds acting on the
endocannabinoid system may have broader application in
treating drug addiction by ameliorating associated traits and
symptoms such as impulsivity and anxiety that perpetuate
drug use and interfere with rehabilitation. As a trait,
impulsivity is known to predispose to addiction and
facilitate the emergence of addiction to stimulant drugs. In
contrast, anxiety and elevated stress responses accompany
extended drug use and may underlie the persistence of drug
intake in dependent individuals. In this article we integrate
and discuss recent findings in rodents showing selective
pharmacological modulation of impulsivity and anxiety by
cannabinoid agents. We highlight the potential of selective
inhibitors of endocannabinoid metabolism, directed at fatty
acid amide hydrolase and monoacylglycerol lipase, to
reduce anxiety and stress responses, and discuss novel
mechanisms underlying the modulation of the
endocannabinoid system, including the attenuation of
impulsivity, anxiety, and drug reward by selective CB2
receptor agonists. Behavioural Pharmacology 26:59–72
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Introduction
Drug addiction is a chronic, relapsing brain disorder
characterized by compulsive drug seeking and repeated
bouts of binge intoxication and withdrawal. Research
over a number of decades has defined the principal
pharmacological mechanisms underlying the primary
reinforcing effects of many substances abused by people,
which directly or indirectly activate the mesolimbic
dopamine (DA) system (Di Chiara and Imperato, 1988;
Nestler, 2005). Yet fundamental questions remain,
including especially how drugs come to dominate beha-
viour so powerfully and why addiction afflicts only a small
subset of all users. A common framework to address these
questions rests on the principle that addiction is a pro-
gressive disorder involving a series of transitions from (i)
initial drug contact and experimentation, (ii) recreational
and mostly occasional use, (iii) a preoccupation to use
drugs more regularly and (iv) consumption levels that
ultimately lead to harm and are life threatening (Everitt
and Robbins, 2005; Belin et al., 2009, 2013; Koob and
Volkow, 2010). Diagnostic criteria of addiction or
substance use disorder, based on the Diagnostic and
Statistical Manual of Mental Disorders, 5th ed. (DSM-5;
American Psychiatric Association), include taking sub-
stances in larger amounts than originally intended, a
persistent desire to cut down or moderate drug use,
longer periods of time using the drug or recovering from
its effects, and intense craving. Neurally, the develop-
ment of addiction is hypothesized to align with the
emergence of drug seeking habits controlled by dopa-
minergic mechanisms in the dorsal striatum and a shift
away from prefrontal cortical control mechanisms
(Jentsch and Taylor 1999; Everitt and Robbins, 2005;
Kalivas and Volkow, 2005; Belin et al., 2013).
Although a distinguishing feature of addiction is a per-
sistent underlying change in the brain reward and stress
systems, caused by protracted drug use (Kalivas and
Volkow, 2005; Nestler, 2005; Koob and Volkow, 2010),
the path to addiction for some may be predestined by
underlying impairments in self-control (Wills et al., 1994;
Verdejo-García et al., 2008; Van den Heuvel et al., 2009).
Indeed, increasing evidence suggests that certain per-
sonality traits, including the seeking out of intense forms
of sensation, novelty, and impulsivity may predispose
to addiction (Sher et al., 2000; Adams et al., 2003;
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Verdejo-García et al., 2008). Moreover, prospective stu-
dies in adolescents unambiguously demonstrate that
impulsivity precedes the onset of drug use and possibly
the development of addiction (Nigg et al., 2006; Wong
et al., 2006), consistent with analogous research in rodents
(Belin et al., 2008; Diergaarde et al., 2008; Economidou
et al., 2009; Dalley et al., 2007).
A complementary view, the opponent process theory,
focuses on progressive drug-induced changes in the
hedonic state of addicts (Koob and Le Moal, 1997). It is
derived from the concept of homoeostasis, the capacity of
an organism to maintain a constant internal environment
despite change, and allostasis, where prolonged contact
with salient stimuli results in adaptations at pathological
set-points. According to this theory addicts take drugs
because they are initially reinforcing. However, with
more protracted drug use not only does this driving
mechanism diminish, a concomitant increase in the
activity of anxiety-related and stress-related circuits
ensues. At this point drug use is driven by compulsive
behaviour and attempts to avoid the aversive reactions
associated with its withdrawal. This hypothesis, there-
fore, emphasizes changes in emotional states, in line with
the view that anxiety and stress contribute to the main-
tenance of addiction (Cleck and Blendy, 2008; Kessler
et al., 2010). The growth of the opponent process gov-
erning negative reinforcement involves reductions in
DA, gamma-amino-butyric acid (GABA) and endogenous
opioid neurotransmission together with facilitated nora-
drenaline (NA) and corticotrophin-releasing factor activ-
ity. Key structures mediating this altered motivational
state include the central amygdala and bed nucleus of the
stria terminalis (Koob, 2013).
Despite considerable research investment a surprisingly
small number of medications have been developed and
approved for the treatment of addiction (Xi, 2011; Pierce
et al., 2012). This deficiency may reflect in part the
dominance over many years of DA-based theories, which
although intuitively attractive have led to no major
breakthroughs in treatment. An alternative approach is to
treat underlying traits that predispose and are often
comorbid with addiction, notably as discussed above
impulsivity and anxiety. Understanding the biological
mechanisms of these addiction-linked behavioural traits
may provide new targets for pharmacological intervention
in addiction. In this article we review putative applica-
tions of drugs targeting the endocannabinoid system in
ameliorating impulsivity and anxiety.
Endocannabinoids are lipid-derived substances found
mainly in the DA-rich basal ganglia, which play a major
role in regulating synaptic function and plasticity in the
striatum (Lovinger and Mathur, 2012). Cannabinoid
receptors in the brain mediate the effects of cannabis (or
marijuana), a widely abused drug that carries significant
adverse health effects, especially among young people
(Volkow et al., 2014). Nevertheless, considerable work,
reviewed below, suggests that pharmacological modula-
tion of the endocannabinoid system can moderate high
levels of anxiety and impulsivity and attenuate the
reinstatement of drug seeking. We first review the
defining features and neural substrates of impulsivity and
anxiety before considering how these addiction-relevant
traits can be selectively modulated by compounds that
facilitate or suppress the function of the endocannabinoid
system. Finally, we discuss the implications of this
research for the treatment of drug addiction.
Impulsivity and addiction
Impulsivity is a heterogeneous construct defining beha-
viours that are premature, poorly planned, inappropriate,
risky and poorly inhibited (Monterosso and Ainslie, 1999;
Evenden, 1999b). Although it can be advantageous to
take risks in certain circumstances, when excessively
and inappropriately expressed, impulsiveness can lead to
suboptimal outcomes (Dickman, 1990). Moreover,
impulsivity has been suggested to contribute to specific
disorders such as addiction, attention deficit hyperactivity
disorder, obsessive–compulsive disorder, bipolar dis-
order, aggression, self-harm and suicidality (Moeller et al.,
2001; Skegg, 2005; Hawton and van Heeringen, 2009;
Coccaro et al., 2011; Bari and Robbins, 2013). As a result,
therefore, there has been a growing interest in investi-
gating the biological mechanisms of impulsivity to facil-
itate the development of new therapies for a range of
neuropsychiatric disorders (Jupp and Dalley, 2014).
Different classifications have been proposed to define
impulsivity, which can be deconstructed in several ways
(Evenden, 1999b). In its simplest forms, impulsivity can
be divided into (i) impulsive action, involving impaired
motor inhibition, and (ii) impulsive choice, defined by
the abnormal preference for small immediate or likely
rewards versus larger-magnitude but delayed or uncertain
rewards (Pattij and Vanderschuren, 2008; Dalley and
Roiser, 2012). On the basis of this dichotomy a variety of
tests have been developed for studying impulsivity in
humans and laboratory animals (Winstanley, 2011; Jupp
et al., 2013). Impulsive action can be assessed as
responses that are premature, mistimed or difficult to
suppress. Some of the main paradigms are the 5-choice
serial reaction time task (5-CSRTT) and its analogues
(Robbins, 2002; Voon et al., 2014), the stop-signal reac-
tion time task (Eagle et al., 2008), the go/no go task
(Harrison et al., 1999) and differential reinforcement of
low rates of responding (Evenden, 1999a). Impulsive
choice can be assessed by tasks that measure aversion for
delayed rewards and are often referred to as delay dis-
counting procedures (Monterosso and Ainslie, 1999; Bari
and Robbins, 2013).
Neurally, impulsivity depends on subregions of the pre-
frontal cortex (PFC), basal ganglia (particularly the ven-
tral region of the striatum), hippocampus, and modulation
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by serotonin (5-HT), DA and NA (Evenden, 1999a,
1999b; Cardinal et al., 2004; Pattij and Vanderschuren,
2008; Dalley et al., 2011; Dalley and Roiser, 2012). In
humans, the delineation of substrates underlying impul-
sivity has relied on neuroimaging and psychological
analysis in healthy individuals and patients with brain
damage or psychiatric disorders such as attention deficit
hyperactivity disorder (Castellanos et al., 2006; Garavan
and Hester, 2007). In experimental animals, considerable
research has shown that distinct corticostriatal ‘loops’
underlie several distinct forms of impulsivity (Winstanley,
2011), including the proposed subdivision of waiting
versus stopping impulsivity (Dalley et al., 2011). Work
over many years has established that impulsivity, in its
many forms, is sensitive to modulation by drugs that affect
monoaminergic transmission, including psychostimulant
drugs (Pattij and Vanderschuren, 2008) and drugs that
block the reuptake of catecholamines in the brain such as
atomoxetine (Economidou et al., 2012; Ansquer et al.,
2014; Feldman and Reiff, 2014). Increasingly, however,
current research has shifted to new targets that offer
putative explanatory mechanisms, including evident
GABA-ergic dysfunction in the nucleus accumbens core
of trait impulsive rats (Caprioli et al., 2014) and pharma-
cological agents that reduce both impulsivity and
addiction-like behaviours in animal models (Jupp and
Dalley, 2014). This research has revealed several pro-
mising lead compounds targeting cholinergic, glutama-
tergic and opioid-ergic transmission, in addition to
continued interest in the endocannabinoid system (Pattij
and Vanderschuren, 2008).
Impulsivity is a widely recognized risk marker for
addiction (Perry and Carroll, 2008; Verdejo-García et al.,
2008; de Wit, 2009) predicting the onset and escalation of
drug use (Diergaarde et al., 2008; Zernicke et al., 2010;
Dalley et al., 2011), rates of relapse (Economidou et al.,
2009; Ersche et al., 2010), and the development of com-
pulsive drug-taking (Belin et al., 2008). It is widely
recognized that impulsive choice for immediate rewards
is present in opiate addicts (Kirby and Petry, 2004),
alcoholics (Vuchinich and Simpson, 1998) and stimulant
abusers (Kirby and Petry, 2004; Monterosso et al., 2007).
Other forms of impulsivity, including impulsive action, as
assessed with such tasks as the stop-signal reaction time
task and go/no go, are evident in alcoholics (Noël et al.,
2007), and abusers of cocaine (Fillmore and Rush, 2002;
Hester and Garavan, 2004) and methamphetamine
(Monterosso et al., 2005). On the basis of the research in
experimental animals different subtypes of impulsivity
appear to affect distinct stages of drug addiction. Thus,
increased impulsive action on the 5-CSRTT was found
to predict an increased motivation to initiate and main-
tain nicotine self-administration, whereas impulsive
choice on a delay discounting procedure predicted
impaired inhibition of drug seeking and an higher prob-
ability for relapse (Diergaarde et al., 2008).
Impulsivity may also arise, in turn, as a consequence of
chronic drug abuse through perturbation of prefrontal
cortical control over basal ganglia function (Jentsch and
Taylor 1999). As a result impulsivity has been hypothe-
sized to facilitate the shift in behavioural control over
drug-taking from the PFC to the striatum, as well as
promoting a maladaptive ventral to dorsal striatal transi-
tion in the control over drug seeking (Everitt and
Robbins, 2005). Elucidating the molecular mechanisms
underlying the transitions from initial drug use to habi-
tual and eventual compulsive drug taking remains an area
of intensive research activity (Belin et al., 2013; Everitt,
2014).
Anxiety and addiction
Anxiety is postulated to contribute to an evolutionary
preserved repertory that prepares and optimizes beha-
vioural and physiological defensive responses for
approaching, confronting, avoiding or escaping innate or
learnt threatening stimuli (Canteras et al., 2010).
However, excessive levels of anxiety may impair perfor-
mance and lead to suboptimal behavioural responses and
ultimately to psychiatric disorders including generalized
anxiety disorder, panic disorder, post-traumatic stress
disorder and obsessive–compulsive disorder. Such dis-
orders are highly prevalent and have significant indivi-
dual and social impacts (Kessler et al., 2010).
Anxiety is often assessed as a subjective state in humans
in conjunction with objective measures of autonomic
function (Canteras et al., 2010). In laboratory rodents,
anxiety-like responses can be quantified by measuring
avoidance or escape responses to innate or conditioned
aversive stimuli. Typical tests include the elevated mazes
and the light–dark shuttle box, which assess ethological
aspects of fear, in addition to tests of conditioned aversive
responses to cues and contexts previously paired with
noxious stimuli (Cryan and Sweeney, 2011; Blanchard
et al., 2013). The neuroanatomical substrates of anxiety-
related behaviours have been extensively investigated
and include the amygdala-ventral striatal interactions
underlying cue-conditioned fear, the hippocampal-
dependent processing of contextual fear, the medial
hypothalamic nuclei and the periaqueductal grey
underlying escape behaviour, and the PFC in stress and
extinction of conditioned aversive responses (Canteras
et al., 2010). A number of neurotransmitters modulate
anxiety-related responses, including GABA and the
monoamines 5-HT and NA, which are the major targets
for currently available anxiolytic drugs, as well as gluta-
mate, DA and the endocannabinoids (Griebel and
Holmes, 2013).
Anxiety and exaggerated stress-related responses are
known to predispose to drug use (Cleck and Blendy,
2008; Kessler et al., 2010) whilst facilitating the acquisi-
tion of stimulant drug self-administration (Piazza and Le
Moal, 1998). Furthermore, the interruption of chronic
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drug consumption results in the emergence of negative
emotional states that lie at the core of the motivational
withdrawal/abstinence syndrome, one of the major cata-
lysts for relapse and persistent drug-taking behaviour
(Koob and Le Moal, 1997, 2008). This shift in motiva-
tional state is a putative consequence of neural adapta-
tions resulting from chronic drug exposure and involves,
in particular, the recruitment of locus coeruleus nora-
drenergic neurons and corticotrophin-releasing factor in
the central nucleus of the amygdala and the bed nucleus
of the stria terminalis (Koob, 2008). Thus, the anxiety
and stress systems of the brain have a major impact on the
escalation and persistence of drug abuse. In experimental
animals, trait anxiety-like behaviour predicts the escala-
tion of intravenous cocaine self-administration, but
not an increased propensity to acquire cocaine self-
administration (Dilleen et al., 2012), indicating that high
anxiety may be a predisposing endophenotype under-
lying the loss-of-control over cocaine intake. These data
further suggest that the mechanisms underlying the
initiation of drug use are not necessarily the same as
those contributing to the development of addiction.
Anxiety also correlates with vulnerability to alcohol
intake. Thus, a high comorbidity between anxiety dis-
orders and alcohol abuse has been reported; this has led
to the tension-reduction hypothesis, which posits that
anxious or stressed individuals tend to consume more
alcohol to alleviate anxiety (Cappell and Herman, 1972;
Pohorecky, 1981; Young et al., 1990). Accordingly,
experimental studies in rats show that higher levels of
anxiety-like behaviour in the elevated plus maze predicts
higher alcohol intake and escalation of intake in volun-
tary drinking procedures compared with low-anxious
animals (Spanagel et al., 1995; Hayton et al., 2012).
Such findings accord with the notion that many drugs
may be used to self-medicate high levels of anxiety and
other negative emotional states (Khantzian, 1985).
Cannabis sativa, cannabinoids and the
endocannabinoid system
Biochemical and neurophysiological processes that
inherent to the endocannabinoid system have been
extensively reviewed elsewhere (Howlett et al., 2002;
Piomelli, 2003; Di Marzo, 2008; Pertwee et al., 2010;
Castillo et al., 2012). Here we provide a brief synopsis of
endocannabinoid pharmacology and its relevance to
impulsivity, anxiety and addiction.
The endocannabinoid system is named after the herb
Cannabis sativa (‘hashish’, ‘marijuana’), which although
widely abused can have beneficial effects in some set-
tings (Zuardi, 2006; Russo, 2007). Its main active con-
stituent Δ9-tetrahydrocannabinol (Δ9-THC) is one of
more than 60 compounds, termed phytocannabinoids,
found in C. sativa (Mechoulam, 1970). The chemical
characterization of this plant and subsequent develop-
ment of synthetic cannabinoids provided the impetus for
the identification and cloning of the major brain expres-
sed cannabinoid-1 (CB1) receptor (Devane et al., 1988;
Matsuda et al., 1990), which is Gi-protein-coupled (Fig. 1)
and densely expressed throughout the brain, particularly
in mesocorticolimbic brain areas (Herkenham et al., 1990,
1991b; Tsou et al., 1998). Soon after the discovery of the
CB1 receptor, the endogenously produced cannabinoid
(endocannabinoid) and arachidonic acid derivative, ara-
chidonoylethanolamide (AEA) was isolated and coined
with the name anandamide after the Sanskrit word for
‘bliss’ (Devane et al., 1992). Subsequently, a second
metabotropic cannabinoid receptor was discovered, the
cannabinoid-2 (CB2) receptor (Munro et al., 1993) as well
as a second endocannabinoid, 2-arachidonoyl glycerol
(2-AG) (Mechoulam et al., 1995). Interestingly, although
CB2 receptors are postulated to be predominately
expressed in the peripheral immune system, with low
expression levels in the brain, CB2 selective compounds
can modulate several centrally mediated processes,
including cocaine reward (Onaivi et al., 2006; Xi et al.,
2011).
The synaptic effects of anandamide are mainly termi-
nated by cellular uptake and hydrolytic catabolism by
fatty acid amide hydrolase (FAAH) (Di Marzo et al., 1994;
Cravatt et al., 1996; Beltramo et al., 1997). By contrast, the
inactivation of 2-AG is mediated by monoacylglycerol
lipase (MAGL) (Dinh et al., 2002). Unlike conventional
neurotransmitters and modulators, endocannabinoids act
as retrograde neural messengers (Wilson and Nicoll,
2002), being synthesized from membrane lipids of post-
synaptic neurons in response to increased neural activity.
Newly synthesized endocannabinoids diffuse across the
synaptic cleft where they activate CB1 receptors located
on presynaptic terminals. The CB1 receptor is coupled to
a myriad of signal transduction mechanisms, initiated by
Gi-protein activation and culminating in the inhibition of
adenylate cyclase, the activation of MAP kinase, inhibi-
tion of calcium influx, and facilitation of potassium efflux.
Collectively, these interactions result in the inhibition of
neuronal activity and neurotransmitter release (Egertova
et al., 1998; Pettit et al., 1998; Kreitzer and Regehr, 2001;
Ohno-Shosaku et al., 2001; Wilson and Nicoll, 2001). It
should be noted, however, that CB1 receptor expression
and function is not necessarily exclusively mediated at
presynaptic terminals and that other receptors and
endocannabinoids have been proposed; these include the
transient receptor potential vanilloid type-1 channel
(TRPV1) for which anandamide may act as the main
endogenous agonist (Starowicz et al., 2007) (Fig. 1).
Cannabinoids are known to regulate the activity of a
number of neuroactive substances through effects
mediated presynaptically by CB1 receptors located on
glutamatergic and GABA-ergic nerve terminals (Katona
et al., 1999; Marsicano and Lutz, 1999; Hermann et al.,
2002; Julian et al., 2003; Katona et al., 2006; Haring et al.,
2007). Activation of CB1 receptors inhibits the release of
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glutamate, GABA and acetylcholine in the nucleus
accumbens (Schoffelmeer et al., 2006) where it also sup-
presses excitatory transmission at glutamatergic synapses
(Robbe et al., 2002; Fig. 2). In addition, stimulation of CB1
receptors increases the firing rate of dopaminergic neurons
and facilitates DA release in the nucleus accumbens
through a GABA-ergic disinhibitory mechanism (Chen
et al., 1990; French, 1997; Tanda et al., 1997; Sperlagh et al.,
2009). Endocannabinoids can therefore strongly influence
information processing in the striatum by modulating DA
inputs not only from the ventral tegmental area (Szabo
et al., 2002; Riegel and Lupica, 2004; Melis et al., 2004b)
but also the substantia nigra zona compacta innervating the
dorsal striatum (Melis et al., 2000; Szabo et al., 2000), as well
as excitatatory glutamatergic afferents from the PFC
(Fitzgerald et al., 2012). CB1 receptors are densely located
in the ventral and dorsal striatum (Herkenham et al., 1990,
1991a; Herkenham, 1992; Tsou et al., 1998) where they are
present on medium spiny neurons (Rodriguez et al., 2001;
Pickel et al., 2006) positive for D1 and D2 receptors
(Hermann et al., 2002; Robbe et al., 2002; Monory et al.,
2007; Martin et al., 2008) and glutamatergic terminals
(Fitzgerald et al., 2012). The endocannabinoid hydrolyzing
enzymes, FAAH and MAGL, are also expressed in the
striatum and related projection areas (Egertova et al., 1998).
Thus, endocannabinoids are ideally placed to fine-tune
processing in mesocorticolimbic brain networks by reg-
ulating inhibitory and excitatory synaptic transmission
(Sidhpura and Parsons, 2011; El Khoury et al., 2012).
The endocannabinoid system and impulsivity
An involvement of the endocannabinoid system in
impulsivity has come to light from current research in
humans and experimental animals. In this regard mar-
ijuana users tend to have higher levels of impulsivity than
nondrug abusing controls (Cousijn et al., 2013; Dougherty
et al., 2013). Acute use of this drug induces altered time
perception, psychomotor and cognitive impairment,
reduced inhibitory control, and increased risk-taking
behaviour (Hall and Solowij, 1998; Iversen, 2003;
Murray et al., 2007). Moreover, Δ9-THC administration to
healthy volunteers elicits impulsive responding on the
stop-signal task but has no effect on delay discounting or
go/no-go discriminative performance (McDonald et al.,
2003). The impairing effect of Δ9-THC on stopping
behaviour has been replicated (Ramaekers et al., 2006b;
Van Wel et al., 2013) and is generally consistent with the
disruptive effects of marijuana on tasks requiring motor
inhibition and risk evaluation (Lane et al., 2005;




























A schema of the currently proposed model for endocannabinoid neurotransmission. Anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are
synthesized and released from postsynaptic membranes to activate Gi-protein-coupled CB1 cannabinoid receptors. This interaction initiates a
cascade of signal transduction mechanisms that include inhibition of adenylate cyclase (AC), activation of MAP kinase (MAPK), inhibition of calcium
influx and facilitation of potassium efflux. AEA also activates transient receptor potential vanilloid type-1 (TRPV1) channels to facilitate calcium influx.
The effects of AEA and 2-AG are terminated by internalization facilitated by a specific membrane transporter (T), followed by hydrolysis by fatty acid
amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively.
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Complementary research in rodents confirms a role of the
endocannabinoid system in specific subtypes of impulsiv-
ity, as summarized in Table 1. Thus, although acute
administration of Δ9-THC was reported not to affect
impulsivity assessed by the 5-CSRTT this substance
decreased impulsivity on a delay discounting task, an effect
that was blocked by the CB1 receptor antagonist/inverse
CB1 receptor agonist, rimonabant (Wiskerke et al., 2011).
In other studies, the synthetic cannabinoid WIN55,212-2
had no effect on impulsivity assessed on a lateralized
reaction time task (Arguello and Jentsch, 2004) or the
5-CSRTT (Pattij et al., 2007). Interestingly, however, this
compound normalized enhanced levels of delay discount-
ing impulsivity in spontaneously hypertensive rats com-
pared with Wistar–Kyoto rats (Adriani et al., 2003). These
rats also exhibit a reduced density of CB1 receptors in the
PFC, suggesting a potential contribution of the endo-
cannabinoid system in this region to the enhanced levels of
impulsivity (Adriani et al., 2003). Anandamide, a non-
selective endogenous ligand exerts a plethora of effects
through multiple mechanisms, including the TRPV1
channel. Systemic administration of this cannabinoid
reduced anticipatory responding (i.e. impulsivity) on the
5-choice task; however this compound also significantly
increased omission errors, possibly reflecting attentional
interference (Panlilio et al., 2009). Intriguingly, these
effects were blocked by the TRPV1 antagonist capsaze-
pine, but not rimonabant. However, the FAAH inhibitor,
URB597, which increases endogenous levels of ananda-
mide, failed to mimic the effects of anandamide (Panlilio
et al., 2009).
To date the majority of studies have focused on the
blockade of the endocannabinoid system in the assess-
ment of impulsivity. Rimonabant has been widely used
for this purpose and has shown to be effective, for
example, in reducing impulsivity on the 5-choice task but
not the delay discounting task (Pattij et al., 2007). This
relatively selective effect on motor impulsivity was later
confirmed and extended to other CB1 receptor antago-
nists (O-2050, SLV330), which unlike rimonabant do not






















Brain loci underlying the modulation of dopamine (DA)-mediated neurotransmission by the endocannabinoid system. Endocannabinoids (eCBs) inhibit
local gamma-aminobutyric acid (GABA)-ergic interneurons that synapse on dopaminergic neurons in the ventral tegmental area (VTA) and substantia
nigra (SNc). In the striatum, eCBs inhibit glutamate (Glut) release from afferents arising from different cortical regions (e.g. prefrontal cortex,
amygdala, hippocampus) and indirectly stimulates dopamine release by inhibiting GABA-ergic interneurons.
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et al., 2011; Wiskerke et al., 2011). Both compounds were
also effective in attenuating the effects of amphetamine
on delay discounting and motor impulsivity (Wiskerke
et al., 2011). Subsequently, rimonabant was shown
to antagonize nicotine-induced motor impulsivity
(Wiskerke et al., 2012) and cocaine-induced impulsivity
in a delay discounting task (Hernandez et al., 2014).
Rimonabant has also been investigated in obese Zucker
rats, which show a preference for immediate, small-
magnitude rewards compared with lean rats. Obese rats
also exhibit increased levels of endocannabinoids and
higher CB1 receptor expression in brain regions that
regulate feeding (Boomhower et al., 2013). Consistent
with a role of CB1 receptors in mediating behavioural
choice in the delay discounting paradigm rimonabant
reduced impulsivity in obese Zucker rats but increased
impulsivity in lean rats (Boomhower et al., 2013). Given
the paucity of studies in this field it is difficult to draw
firm conclusions. Nevertheless, CB1 receptor antagonists
appear to reduce impulsivity in a baseline-dependent
manner, particularly when this behaviour is elevated in
various trait models or evoked by psychostimulant drugs.
Interestingly, the same profile of effects can be achieved
using selective CB2 receptor agonists (e.g. JWH133) in
DBA/2 mice, which express a number of behaviours,
including some that appear to reflect increased impul-
sivity (Navarrete et al., 2012). Notably, DBA/2 mice also
show higher levels of CB2 receptor expression in the
cingulate cortex, nucleus accumbens, and amygdala
compared with a less impulsive mouse strain (Navarrete
et al., 2012).
The studies reviewed above have mainly investigated
the acute effects of cannabinoids on impulsivity. Yet an
important question is whether evident neurocognitive
impairment in adolescent cannabis users (Hester et al.,
2009; Gonzalez et al., 2012; Solowij et al., 2012), including
increased risky and impulsive decision-making (Solowij
et al., 2012), extends well into adulthood. Possibly rele-
vant to this question are data showing that inhibition of
anandamide hydrolysis during adolescence, a manipula-
tion that persistently stimulates endocannabinoid recep-
tors, blocked the expected increase in impulsivity of
adult rats previously deprived of early maternal contact
(Marco et al., 2007). This interesting and potentially
important study merits further research to understand
how the endocannabinoid system influences the devel-
opmental trajectory of inhibitory control circuitry during
adolescence, which also has an impact on social beha-
viours during this period (Trezza and Vanderschuren,
2008; Trezza et al., 2014).
The endocannabinoid system and anxiety
The involvement of the endocannabinoid system in
anxiety has been more extensively investigated than its
role in impulsivity (Viveros et al., 2005; Moreira and Lutz,
2008; Moreira and Wotjak, 2010; Marco et al., 2011).
C. sativa induces a well-described state of relaxation and
reduced anxiety; unfortunately, however, this has not
been easily demonstrated in experimental settings.
Studies administering pure Δ9-THC or synthetic CB1
receptor agonists to laboratory animals report complex
findings, which depend on the dose, route of
Table 1 A summary of the effects of acute pharmacological interventions on the endocannabinoid system on two major subtypes of
impulsivity in experimental animals
Substance (dose) Subjects Impulsive action Impulsive choice References
Cannabinoids
Δ9-THC (0.5, 1, 2a mg/kg) Wistar rats = ↓ Wiskerke et al. (2011)
WIN55,212–2 (2a mg/kg) Wistar–Kyoto rats X = Adriani et al. (2003)
Spontaneously hypertensive rats (highly impulsive) X ↓
WIN55,212–2 (1, 2.5 mg/kg) Long-Evans rats = X Arguello and Jentsch (2004)
WIN55,212–2 (0.3, 1, 3 mg/kg) Wistar rats = = Pattij et al. (2007)
CB1 receptor antagonists/inverse agonists
Rimonabant (0.1, 0.5, 1 mg/kg) Long-Evans rats = X Arguello and Jentsch (2004)
Rimonabant (0.3a, 1a, 3a mg/kg) Wistar rats ↓ = Pattij et al. (2007)
Rimonabant (1a, 3a mg/kg) Wistar rats ↓ = Wiskerke et al. (2011)
↓b ↑c
Rimonabant (1, 3a mg/kg) Wistar rats ↓d X Wiskerke et al. (2012)
= e X
Rimonabant (1a, 3, 10a mg/kg) Lean Zucker rats X ↑ Boomhower et al. (2013)
Obese Zucker rats(highly impulsive) X ↓
Rimonabant (1.5 mg/kg) Long-Evans Rats X ↓f Hernandez et al. (2014)
O-2050 (0.3a, 1a, 3a mg/kg) Wistar rats ↓ = Wiskerke et al. (2011)
↓b ↑c
SLV330 (1, 3a, 10a mg/kg) Wistar rats ↓ X De Bruin et al. (2011)
Modulation of stimulant-induced changes in impulsivity.






fChronic cocaine-induced high impulsivity.
Endocannabinoids and addiction Moreira et al. 65
administration, and animal species used (Viveros et al.,
2005). Also, the effects of CB1 receptor agonists depend
on environmental stress, which may vary between dif-
ferent laboratories. As a general rule, however, low doses
of cannabinoids tend to have anxiolytic effects, whereas
higher doses induce anxiogenic effects (Moreira and
Wotjak, 2010; Marco et al., 2011). Finally, the anxiolytic-
like properties of CB1 receptor agonists are often
restricted by nonspecific motor impairment resulting in
narrow dose–response effects. Despite this complexity,
however, the anxiolytic-like effects of CB1 receptor
agonists can be reliably detected under appropriate doses
and experimental conditions (Moreira and Lutz, 2008).
As an alternative, drugs that increase endogenous levels of
anandamide by inhibiting its neuronal internalization and/
or hydrolysis diminish anxiety-like responses in animals
with a more favourable pharmacological profile compared
with CB1 receptor agonists (Moreira and Wotjak, 2010).
Anandamide is normally produced and released at low
physiological levels but its synthesis and release increases
in response to increased neural activation (Piomelli, 2003).
Interestingly, FAAH inhibitors, which increase ananda-
mide levels, appear to have more consistent effects on
anxiety responses under highly aversive conditions, pre-
sumably because anandamide appears to be recruited as a
protective mechanism in response to stress (Kathuria et al.,
2003; Patel and Hillard, 2006; Naidu et al., 2007; Moreira
et al., 2008). Recent research has revealed that blocking the
degradation of 2-AG may also be a useful approach to
reduce anxiety-like responses (Busquets-Garcia et al.,
2011). Endocannabinoid hydrolysis inhibitors may there-
fore be a promising strategy for developing new anxiolytic
drugs (Batista et al., 2014). Intriguingly, the effect of
MAGL inhibitors appears to be mediated by CB2 rather
than CB1 receptors (Busquets-Garcia et al., 2011) and
confirms recent interest in the CB2 receptor as a target to
modulate aversive responses (Garcia-Gutierrez et al., 2012).
Alternative potential targets include: (i) the TRPV1 chan-
nel, whose function in modulating anxiety seems to be
diametrically opposite to the CB1 receptor (Moreira and
Wotjak, 2010; Moreira et al., 2012b); (ii) dual FAAH and
TRPV1 blockade (Micale et al., 2009) and (iii) site-specific
inhibition of cyclo-oxygenase (Hermanson et al., 2013).
The effects of CB1 receptor antagonists/inverse agonists,
particularly rimonabant and AM251, have been exten-
sively investigated in experimental animals and, in the
case of rimonabant, in humans as well (Bergamaschi et al.,
2014). Most studies demonstrate that these compounds
tend to magnify responses to aversive stimuli in mice and
rats. Thus, in tests used to assess anxiety, they exert
anxiogenic-like effects (Moreira and Wotjak, 2010) and
impair the extinction of conditioned aversive memories
(Marsicano et al., 2002). CB1 receptor blockade also
interferes with stress coping responses and increases the
activation of the neuroendocrine stress axis, with possible
implications for mood regulation in humans (Hill et al.,
2009; Gunduz-Cinar et al., 2013). These preclinical data
have been confirmed in humans treated with rimonabant
for obesity. The clinical efficacy of rimonabant was
similar to other antiobesity drugs, with a modest reduc-
tion in body weight, but unfortunately its use was
accompanied by anxiety, depression and suicidal
thoughts (Moreira and Crippa, 2009). The CB1 receptor
exhibits constitutive activity when expressed in artificial
cell systems, in which rimonabant and other cannabinoid
blockers act as inverse agonists. Thus, neutral antagonists
have been investigated as a safer alternative to reduce
CB1-mediated signalling (McLaughlin, 2012) These
compounds reduce body weight similarly to rimonabant,
without inducing anxiogenic-like effects or reducing
motivation for reward in rats (Sink et al., 2010; Meye et al.,
2013). This research opens the interesting possibility of
dissociating the effects of CB1 receptors on motivation
and aversion based on constitutive receptor activity, with
potential therapeutic implications. A summary of the
predominant effects on anxiety of pharmacological
interventions that target the endocannabinoid system is
shown in Table 2.
The neuroanatomical loci underlying the effects of
cannabinoid-related compounds on anxiety have been
extensively investigated using selective molecular
approaches and intracranial pharmacology. As anticipated
from their behavioural pharmacological profile, cannabi-
noids modulate brain regions involved in generating
defensive responses against stressful and threatening
stimuli, including the medial PFC, amygdala, hippo-
campus and the midbrain periaqueductal grey (Moreira
et al., 2012a). Neurochemically, these effects involve
interactions with various neurotransmitters and neuro-
modulators, including GABA, glutamate, 5-HT and DA
(Marco et al., 2004; Bambico et al., 2010; Terzian et al.,
2011; Rey et al., 2012). Through such mechanisms,
facilitation of the endocannabinoid system leads to a
reduction in aversive responses to both innate and
Table 2 A summary of the effects of genetic and pharmacological
interventions on the endocannabinoid system on anxiety-like
responses
Target
Main effects of pharmacological
activation on anxiety
Main effects of pharmacological or







↓, anxiolytic; ↑, anxiogenic; ?, unclear; AT, membrane anandamide transporter;
CB1, cannabinoid type-1 receptor; CB2, cannabinoid type-2 receptor; FAAH,
fatty acid amide hydrolase; MAGL, monoacylglycerol lipase; TRPV1, transient
receptor potential vanilloid type-1 channel.
aTends to be anxiolytic at low doses and anxiogenic at high doses.
bIncrease anxiety particularly under highly aversive environments.
cInverse agonists are more anxiogenic than neutral antagonists.
dAnxiolytic-like effects tent to be more consistent under highly aversive environ-
ment.
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conditioned threatening stimuli whilst facilitating the
extinction of already acquired aversive responses
(Moreira and Wotjak, 2010; Marco et al., 2011).
Implications for addiction
On the basis of the research findings reviewed above
some general conclusions can be made about the putative
efficacy of cannabinoid-based compounds to treat addic-
tion. Impulsivity and anxiety have been extensively
investigated as behavioural endophenotypes in addiction
(Koob and Le Moal, 1997, 2008; Jentsch and Taylor 1999;
Everitt et al., 2008; Dalley et al., 2011; Ersche et al., 2012)
where their causal impacts appear to manifest at quite
distinct stages of the addiction process. Specifically,
whereas impulsivity is widely regarded as an antecedent
behavioural marker involved in the initiation of drug use
and in facilitating the development of stimulant addiction
(Kreek et al., 2005; Belin et al., 2008; Koob and Le Moal,
2008; Dalley et al., 2007) anxiety is considered to have its
greatest impact following protracted drug use where
continued drug intake increasingly comes to depend on
negative reinforcement mechanisms (Koob and Le Moal,
2008). Leaving aside the possibility that the separation
between impulsivity and anxiety, in terms of temporally
distinct risk markers for addiction, could be driven in part
by the class of predominately abused drug (i.e. stimulants
vs. opiates/alcohol) cannabinoid-based treatments may
have utility during both the early and late stages of
addiction. Thus, for example, whereas natural and syn-
thetic cannabinoids reduce inhibitory control and increase
risk-taking behaviour (Tanda et al., 1997; Giuffrida et al.,
1999; Melis et al., 2004a; Lafourcade et al., 2007; Pillolla
et al., 2007; Sperlagh et al., 2009; Chiu et al., 2010), CB1
receptor antagonists generally strengthen impulse control
(Pattij et al., 2007) thereby putatively reducing the
initiation of drug abuse and later emergence of compul-
sive drug intake in vulnerable individuals (Fig. 3).
Notably, CB1 receptor antagonists attenuate several
drug-evoked/motivated behaviours, including sensitiza-
tion, self-administration and reinstatement (De Vries
et al., 2001; Gerdeman et al., 2008; Xi et al., 2008).
Likewise, CB1 receptor antagonists block the acquisition
and expression of nicotine-induced conditioned place
preference in rats and mice (Le Foll and Goldberg, 2004;
Merritt et al., 2008) and reduce self-administration of this
drug (Cohen et al., 2002; Shoaib, 2008). CB1 receptor
antagonists also reduce opioid and alcohol intake.
Indeed, there is evidence for functional interactions
between the endogenous cannabinoid and opioid sys-
tems. Thus, CB1 receptor antagonists and genetic dele-
tion of the CB1 receptor impair conditioned place
preference and self-administration of morphine and her-
oin (Navarro et al., 2001; De Vries et al., 2003; Solinas
et al., 2003). Moreover, CB1 receptor antagonists reduce
ethanol consumption and conditioned place preference
(Arnone et al., 1997; Wang et al., 2003; Economidou et al.,
2006). In addition, CB1 receptor knock-out mice show
reduced responses to alcohol (Houchi et al., 2005; Thanos
et al., 2005).
There is thus substantial evidence that CB1 receptor
antagonists reduce responses to drugs of various classes,
including cocaine, nicotine, opioids and alcohol (for a
detailed review, see Serrano and Parsons, 2011). It should
be noted, however, that CB1 receptor antagonists can
augment the consequences of aversive stimuli, as dis-
cussed above, and may therefore be more appropriate as
therapeutic agents for individuals in which impulsivity,
rather than anxiety, is the driving endophenotype in
addiction. In this regard, neutral antagonists, lacking
inverse agonistic actions, might represent a superior
approach, as discussed above. In addition, interventions
targeting the CB2 receptor may have utility since selec-
tive CB2 receptor agonists reduce impulsivity (Navarrete
et al., 2012), as well as the primary reinforcing actions of
cocaine, effects that are presumed to depend on the
mesocorticolimbic dopaminergic systems (Xi et al., 2011).
Furthermore, pharmacological blockade or genetic dele-
tion of this receptor reduces nicotine-induced condi-
tioned place preference and self-administration in mice
(Navarrete et al., 2013). CB2 receptor knock-out mice also
exhibit increased responses to ethanol in both condi-
tioned place preference and self-administration para-
digms (Ortega-Álvaro et al., 2013). However, the precise
mechanism through which CB2 receptors modulate drug-
motivated behaviours requires further elucidation.
Therapies targeting the endocannabinoid system may be
useful adjuncts to treat anxiety and elevated stress asso-
ciated with chronic addiction (Fig. 3). As reviewed above,
much research suggests that the endocannabinoid system
functions as a protective mechanism against diverse
forms of aversive stimuli and is a key modulator of
anxiety, stress and depression (Hill et al., 2009; Moreira
and Wotjak, 2010; Gunduz-Cinar et al., 2013). Natural
and synthetic CB1 receptor agonists can attenuate
anxiety-like behaviour at specific doses but with ancillary
effects on motor and mnemonic functions and with
attendant psychotomimetic effects, these compounds do
not represent an attractive approach to treat addiction.
Indeed, CB1 receptor stimulation can facilitate drug-
induced and cue-induced relapse, possibly by indirectly
stimulating the dopaminergic mesocorticolimbic path-
ways (Fattore et al., 2007). As an alternative, the CB2
receptor has emerged as a potential target for alleviating
anxiety (Garcia-Gutierrez et al., 2012) and reportedly
reducing impulsivity in rodents (Navarrete et al., 2012).
In addition, FAAH inhibitors selectively enhance the
‘on-demand’ actions of anandamide and attenuate anxi-
ety and stress responses (Moreira et al., 2012b). Thus,
FAAH, and possibly MAGL inhibitors as well, may be
useful therapies to alleviate withdrawal symptoms that
trigger relapse and perpetuate drug use (Panlilio et al.,
2013).
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Conclusion
The research findings reviewed in this article indicate
that pharmacological interventions that selectively target
the endocannabinoid system can moderate the expres-
sion of impulsivity and anxiety, two behavioural endo-
phenotypes that predispose to the development of drug
addiction. The effects of such agents are mediated within
the basal ganglia, including especially the striatum and
limbic afferents to this region from the PFC, hippo-
campus and amygdala. Although this field is still rela-
tively nascent, findings to date suggest several promising
leads for research, not least the delineation of specific
functions and molecular targets of anandamide and 2-AG,
and the clear value of additional studies to define the
neuropsychopharmacology of selective CB2 receptor
agonists, which show promise as novel therapies in
addiction. Such research may reveal novel mechanisms
underlying the aetiology of predisposing behavioural
endophenotypes in addiction, thereby enabling the
development of new therapies to facilitate abstinence
and rehabilitation.
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